Clinical Trial Search

N/A N=138 Reverse Medical Barrel™ Device for Adjunctive Treatment for Wide-Neck, Intracranial, Bifurcating/Branching Aneurysms

Intracranial Bifurcating Aneurysms

Primary: Number of Participants With Neurologic Death or Major Ipsilateral Stroke Within 12 Month Follow-up Period. — 5 Participants

Medtronic Neurovascular Clinical Affairs Results Dec 2018 34.7% serious AE View details

N/A N=11 Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

Schizophrenia · Schizoaffective Disorder

Primary: MATRICS Consensus Cognitive Battery (MCCB) Change in Neurocognitive/Functional Measures — 39.8; 38.2 z-score

Icahn School of Medicine at Mount Sinai Results Dec 2018 0.0% serious AE View details

Phase 3 N=1,315 Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

Alzheimer's Disease

Primary: Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24 — 0.39; 0.75 units on a scale — p=0.2249

Axovant Sciences Ltd. Results Dec 2018 1.8% serious AE View details

N/A N=299 Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Degenerative Joint Disease · Congenital Deformity · Arthritis

Primary: Pain on Weight Bearing — 71.0; 70.7; 29.5; 28.2 units on a scale

BioMimetic Therapeutics Results Dec 2018 18.4% serious AE View details

Phase 2 N=30 Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Juvenile Myelomonocytic Leukemia

Primary: Percent Probability of Event-free Survival (EFS) — 83; 22 percent probability

Children's Oncology Group Results Dec 2018 7.4% serious AE View details

Phase 3 N=667 This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

Epilepsy

Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study Period — 91.2 percentage of participants

UCB PHARMA Inc. (US) Results Dec 2018 22.8% serious AE View details

Phase 2 N=756 Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Breast Cancer

Primary: False Negative Rate (FNR) for Sentinel Lymph Node (SLN) Surgery After Chemotherapy When at Least 2 SLNs Were Excised in Women Initially Presenting With Biopsy-proven cN1…

Alliance for Clinical Trials in Oncology Results Dec 2018 0.8% serious AE View details

N/A N=148 Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery

Pain, Postoperative

Primary: Cumulative Postoperative Opiate Consumption — 2.9; 3.8; 5.7 mg

Medical University of South Carolina Results Dec 2018 0.0% serious AE View details

N/A N=40 Ridge Preservation With Platelet Rich Fibrin Augmented With Freeze Dried Bone Allograft

Alveolar Ridge Preservation

Primary: Percentage of Vital Bone — 46; 39; 29; 40 percentage of vital bone

University of California, San Francisco Results Dec 2018 0.0% serious AE View details

Phase 3 N=176 A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants

Opioid Dependence

Primary: The Primary Efficacy Endpoint is a Responder Rate Analysis, Where a Responder is Defined as a Patient With no More Than 2 of 6 Months With Any Evidence of Illicit Opioid…

Titan Pharmaceuticals Results Dec 2018 2.8% serious AE View details

N/A N=200 Effect of Pulmonary Recruitment Maneuver (PRM) on Pain and Nausea After Laparoscopic Bariatric Surgery

Pain, Postoperative · Postoperative Nausea and Vomiting

Primary: Postoperative Pain — 3; 2; 2; 3 score on a scale

Region Östergötland Results Dec 2018 0.0% serious AE View details

Phase 3 N=430 Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid

Primary: Percentage of Patients With Drug-related Adverse Events (AEs) During the Treatment Phase — 21.3; 20.4; 17.6 Percentage of patients (%)

Boehringer Ingelheim Results Dec 2018 6.1% serious AE View details

Phase 2 N=58 Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer

Breast Cancer

Primary: Progression-free Survival (PFS) Until First Progression — 2.0; 5.7 months

Emory University Results Dec 2018 12.1% serious AE View details

Phase 2 N=39 Effects of Atomoxetine in Mild Cognitive Impairment

Mild Cognitive Impairment

Primary: Change in Interleukin 1 (IL 1-alpha) in Cerebrospinal Fluid (CSF) in Subjects With Mild Cognitive Impairment (MCI) Treated With Atomoxetine/Inactive Compound Compared to…

Emory University Results Dec 2018 7.9% serious AE View details

Phase 3 N=323 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Bilateral Nasal Polyposis

Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.26; -0.53; -0.56; -0.67 units on a scale

Optinose US Inc. Results Dec 2018 0.7% serious AE View details